Ebola haemorrhagic fever virus: pathogenesis, immune responses, potential prevention
- PMID: 25694094
Ebola haemorrhagic fever virus: pathogenesis, immune responses, potential prevention
Abstract
Ebola zoonotic RNA filovirus represents human most virulent and lethal pathogens, which induces acute hemorrhagic fever and death within few days in a range of 60-90% of symptomatic individuals. Last outbreak in 2014 in West Africa caused panic that Ebola epidemic can be spread to other continents. Number of deaths in late December reached almost 8,000 individuals out of more than 20,000 symptomatic patients. It seems that only a coordinated international response could counteract the further spread of Ebola. Major innate immunity mechanisms against Ebola are associated with the production of interferons, that are inhibited by viral proteins. Activation of host NK cells was recognized as a leading immune function responsible for recovery of infected people. Uncontrolled cell infection by Ebola leads to an impairment of immunity with cytokine storm, coagulopathy, systemic bleeding, multi-organ failure and death. Tested prevention strategies to induce antiviral immunity include: i. recombinant virus formulations (vaccines); ii. cocktail of monoclonal antibodies (serotherapy); iii. alternative RNA-interference-based antiviral methods. Maintaining the highest standards of aseptic and antiseptic precautions is equally important. Present brief review summarizes a current knowledge concerning pathogenesis of Ebola hemorrhagic disease and the virus interaction with the immune system and discusses recent advances in prevention of Ebola infection by vaccination and serotherapy.
Keywords: Ebola virus disease pathogenesis; immunity; vaccination.
Similar articles
-
General introduction into the Ebola virus biology and disease.Folia Med Cracov. 2014;54(3):57-65. Folia Med Cracov. 2014. PMID: 25694096 Review.
-
[Ebola virus disease].Folia Med Cracov. 2014;54(3):5-16. Folia Med Cracov. 2014. PMID: 25694090 Review. Polish.
-
Ebola virus disease - pathogenesis, clinical presentation and management.Folia Med Cracov. 2014;54(3):49-55. Folia Med Cracov. 2014. PMID: 25694095 Review.
-
The evolution of Ebola virus disease outbreaks.Folia Med Cracov. 2014;54(3):27-32. Folia Med Cracov. 2014. PMID: 25694092 Review.
-
Ebola virus disease in Africa: epidemiology and nosocomial transmission.J Hosp Infect. 2015 May;90(1):1-9. doi: 10.1016/j.jhin.2015.01.002. Epub 2015 Jan 20. J Hosp Infect. 2015. PMID: 25655197 Review.
Cited by
-
Effects of vaccines in protecting against Ebola virus disease: protocol for a systematic review.BMJ Open. 2019 Jul 3;9(7):e029617. doi: 10.1136/bmjopen-2019-029617. BMJ Open. 2019. PMID: 31272985 Free PMC article.
-
The cellular protein phosphatase 2A is a crucial host factor for Marburg virus transcription.J Virol. 2024 Sep 17;98(9):e0104724. doi: 10.1128/jvi.01047-24. Epub 2024 Aug 28. J Virol. 2024. PMID: 39194238 Free PMC article.
-
Potential benefits, mechanisms, and uncertainties of convalescent plasma therapy for COVID-19.Blood Sci. 2020 Jun 24;2(3):71-75. doi: 10.1097/BS9.0000000000000047. eCollection 2020 Jul. Blood Sci. 2020. PMID: 35402827 Free PMC article. Review.
-
Regulation and functions of the NLRP3 inflammasome in RNA virus infection.Front Cell Infect Microbiol. 2024 Jan 5;13:1309128. doi: 10.3389/fcimb.2023.1309128. eCollection 2023. Front Cell Infect Microbiol. 2024. PMID: 38249297 Free PMC article. Review.
-
Pulmonary Involvement during the Ebola Virus Disease.Viruses. 2019 Aug 24;11(9):780. doi: 10.3390/v11090780. Viruses. 2019. PMID: 31450596 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical